• Effects of 5FU chemobrain were tested using a novel spatial DRL paradigm.
Introduction
Chemotherapy-induced cognitive impairment, commonly referred to as chemobrain, affects between 17% and 75% of chemotherapy patients [1] . Human participants show deficits in memory, executive function, and processing speed [2] . Deficits in spatial memory, spatial learning, and spatial recognition tasks tend to occur with rodents [3, 4] , although results are mixed [4, 5] . Unfortunately, there is little existing communication between human and animal chemobrain research [4, 6] , thus obscuring findings and hampering the potential for effective treatment. There are few animal studies, for example, evaluating multidimension tasks similar to those used in human studies [(e.g. spatial and temporal components) [4, 6] ]. Using multiple dimensions in behavioral tasks may more reliably produce frontal cortex dysfunction in rodents observed with more complex tasks [7, 8] . Often, operant procedures are used to incorporate multiple dimensions of behavior, however, there are few examples in the chemobrain literature [3, 7] . Incorporating multiple dimensions into behavioral tasks (e.g. spatial and temporal) using operant procedures may increase the cognitive difficulty of the paradigm and enhance opportunities to isolate behavioral parameters. Further, operant tasks may more closely resemble functional characteristics of human behavioral paradigms and real world cognitive processes [6] . Operant paradigms may allow for more robust independent variable parameters in conjunction with the ability to link different behavioral parameters to corresponding neurochemical processes.
Another barrier to effective treatment is that the underlying mechanism of chemobrain is unknown [9, 10] . The etiology of chemobrain is often investigated using the drug 5-fluoruoracil (5-FU) because 5-FU is one of the most commonly used chemotherapeutic agents in treatment [11] . Exploratory treatments such as physical activity [12] , cognitive training [13] , and pharmacological agents [14] have shown promise, albeit with mixed results [4, 15] . Existing evidence suggests 5-FU causes degeneration of myelin integrity in animal subjects [16] and that this breakdown (e.g. demyelinated axons in the corpus callosum) corresponds to hippocampal neurodegenerative deficits that progressively grow worse over time. Proposed mechanisms are oxidative stress [17] , mitochondrial dysfunction [18] and hippocampal neurodegeneration [19] .
The small molecule drug KU-32 may provide neuroprotective effects during 5FU treatment. KU-32 is a C-terminal inhibitor of the molecular chaperone of heat shock protein 90 [(Hsp 90) [20] ], and has neuroprotective effects on electrophysiological, bioenergetic, and morphologic systems related to diabetic neuropathy [21, 22] . KU-32 repairs mitochondrial dysfunction preventing myelin degradation, an underlying condition of a variety of neurodegenerative disorders [10] . The drug produces a series of reactions initiated by inherent ATP and molecular chaperones Hsp90 and Hsp70 in order to induce a cytoprotective heat shock response. KU-32 decreases neurodegeneration through multiple related mechanisms [22, 23] and may protect cells from a variety of damaging mechanisms induced by 5-FU. One purpose of this study was to determine if KU-32 + 5-FU would result in neuroprotective effects as observed in a multi-dimensional evaluation of cognitive functioning.
Operant research utilizing differential reinforcement of low rates (DRL) of responding in conjunction with a spatial discrimination task may be an ideal avenue to incorporate multi-dimensional components (i.e. spatial and temporal) in an animal chemobrain paradigm. DRL procedures require subjects to wait a minimum amount of time between successive responses to receive reinforcement [24] . A target response that occurs prior to the end of the interval resets the interval. Such a procedure may allow for particularly sensitive measurement of drug-related treatments, as the animal must simultaneously incorporate timing and spatial skills to earn food rewards. The current study therefore evaluated the protective effects of KU-32 + 5FU in comparison to 5FU alone using a group design across three treatment points. Multiple time points were used to compare more acute vs. longer-term effects within and across groups.
Method

Subjects
Eleven Wistar rats from Charles River (Raleigh, NC) were maintained on a 22-h deprivation schedule. Rats earned food pellets (45 mg, Bio-Serv, Frenchtwon, NJ) during 1-h experimental sessions and then received ad libitum food for the remainder of the 2-h access period beginning approximately 10 min after session. Rats were housed and fed in pairs but were monitored and fed individually in cases wherein dominance relations developed. The rats were 5 months old at the beginning of the experiment, had previous experience earning food on schedules of reinforcement, water was freely available in the home cages, and cages were located in a colony room with a 12 h:12 h light-dark cycle. Sessions occurred during the light phase of this cycle. All procedures were in accordance with the guidelines established by the University of Kansas Institutional Animal Care and Use Committee.
Apparatus
Behavioral sessions were conducted in standard MedPC operant chambers (30.5 cm long, 24.1 cm wide, 29.2 cm high; Med Associates, Inc., St. Albans, VT) illuminated by 28-V houselights centered on the back wall (26.7 cm from the floor). Centered on the front wall, 1 cm above the floor grid was a pellet receptacle (3 cm × 4 cm) into which a pellet dispenser dispensed pellets. On the curved, rear wall were five side-by-side nose-poke access openings (2.54 cm × 2.54 cm), each illuminated by a cue light and featuring infrared response recording. Nose-poke openings were 2.54 cm apart and 2 cm from the floor. Chambers were housed in sound attenuating cabinets with white noise fans.
Procedure
Behavioral testing was performed a minimum of six out of every seven days, at approximately the same time each day, for four weeks. There was no pre-training performed because rats had previous experience with schedules of reinforcement. All rats experienced 12-14 sessions prior to the experimental phase and twice received saline interveinous (i.v.) and saline oral gavage administrations immediately following behavioral sessions. For the experimental phase, rats were randomly placed into one of two groups (KU32 + 5-FU or SAL + 5FU). The experimental phase for each rat began following the first administration of 5-FU and KU32/SAL. A second administration occurred one week later. Behavioral data was collected up to one week following the second administration.
Behavioral testing
Rats began behavioral sessions on differential reinforcement of low-rate 20-s schedules of reinforcement (DRL20). Food pellets were contingent on successive nose-poke responses in the center nose-poke opening (NP3) with inter-response times (IRTs) greater than or equal to 20 s. An NP3 response with an IRT less than 20-s reset the interval, such that the IRT between the resetting response and the subsequent response needed to be 20 s in order to earn a reinforcer. Nose-poke responses on the other four nose-poke openings were recorded but did not reset the interval or earn reinforcement. DRL20 schedules moved to DRL40 schedules prior to the experimental phase for all but two rats.
Drug administration
All injections took place within 2 h following behavioral sessions. All rats received an i.p. saline injection and an oral gavageadministered dose of saline twice (one week removed) prior to the treatment phase to reduce the potential for vehicle-specific effects on behavior during the treatment phase. Rats received drug administration twice over the course of treatment, with the second administration occurring exactly one week removed from the start of treatment. 5-FU was administered by i.v (tail vein) and KU-32 or saline control was administered via oral-gavage. Oral gavage (KU-32 or SAL) was administered immediately prior to 5-FU injections. All injections occurred after behavioral sessions for that particular day.
Data analysis
Data were collected the first day following the first set of injections (i.e. Day 1), the first day following the second set of injections (i.e. Day 7), and exactly one week following the second set of injections (Day 14). To derive overall DRL performance, reinforcers at each time point for each rat were summed and then averaged for each group. For measurement of temporal discrimination, total NP3 responses were divided by total reinforcers and the mean was calculated at each time point for each group. Two-way ANOVAs were used to compare both reinforcers earned and temporal discrimination. Sidak's multiple comparison tests were used as needed to test individual time point differences at treatment time points (i.e. Day 1, Day 7, and Day 14).
Level of responding and degree of spatial discrimination across the treatment phase (i.e. D1, D7, and D14) were evaluated. Level of responding was calculated by taking mean nose-poke responses in relation to each nose-poke target for both groups at each time point. Degree of spatial discrimination was measured by taking the average nose-poke data to plot Gaussian functions for each group at each time point. The Gaussian function can be summarized into one index measure by taking the width of the curve at the points when the $y$-axis is half of the maximum height (i.e. full-widthhalf-maximum, FWHM):
The standard deviations of Gaussian distributions for each group per time point were averaged and multiplied by 2.355 to derive FWHM (i.e. degree of spatial discrimination). Two-way ANOVA tests were used for both level of responding and degree of spatial discrimination to evaluate differences between the two-groups and across the three time points. Sidak's multiple comparison tests were used as needed to test individual time point differences at treatment time points. The top panel of Fig. 2 shows mean reinforcers earned divided by total NP3 responses across D1, D7, D14 for rats in the 5-FU + KU32 (squares) and 5-FU + Saline (circles) groups. There were significant main effects of group (F = 13.3, p = 0.001), time point (F = 3.5, p = 0.046), and the interaction of group and time point (F = 5.9, p = 0.008). Post hoc comparisons revealed that those rats in the KU32 + 5FU group were significantly more efficient in their reinforcers/total NP3 responses than those in the Saline + 5FU group at D14 (p = 0.0001). Within groups, there were no significant differences across time points within the 5FU group, however, those rats in the 5FU + KU32 group were significantly more efficient in their reinforcers/NP3 responding at D14 compared to D1 (p = 0.002) or D7 (p = 0.002). Fig. 3 shows mean nose-poke responses (y-axis) per nose-poke target (x-axis) for both 5FU + Saline (open squares) and 5FU + KU32 rats (open circles) for D1 (top panel), D7 (middle panel), and D14 (bottommost panel). Gaussian curves are fit to each group's mean responses across each target at a given time point (i.e. D1, D7, and D14). To determine level differences in responses between the two groups, two-way ANOVAs comparing mean responses across nosepoke targets were used. Significant differences were only observed between the groups on D14 such that the 5FU + Saline group exhibited more responses than the 5FU + KU32 group. A post hoc comparison revealed that the only significant difference in mean responses between the groups on D14 was at NP3 (p = 0.006). An index of the Gaussian gradient (FWHM) was derived for each group at each time point. A two-way ANOVA revealed non-significant findings for group (p = 0.23) and time point (p = 0.26) suggesting no differences in spatial discrimination across the two groups.
Results
Discussion
The current data demonstrated pharmacological prevention of temporal-discrimination deficits induced by 5FU with the use of the novel drug, KU32. The current study is the first to our knowledge to demonstrate maintained pharmacological prevention of chemotherapy induced cognitive impairments in a temporalspatial discrimination task. Rats from the 5FU + KU32 group and the 5FU + Saline group exhibited nearly identical overall DRL performance on all measures immediately following the first set of injections (D1). When evaluated immediately following their second set of injections (D7) and one week following their second set of injections (D14), however, the 5FU + KU32 group earned significantly more reinforcers than the 5FU + Saline group. In addition, rats who received 5FU + KU32 showed superior temporal discrimination compared to the 5FU + Saline group and significantly improved their temporal discrimination from D7 to D14. Lastly, there were no significant differences in the spatial discrimination between the two groups, but the 5FU + Saline group showed significantly higher levels of NP3 responding, highlighting the temporal discrimination deficits. There are three further points to note.
First, the current study on chemobrain is the first to our knowledge to use simultaneous temporal and spatial requirements within an operant procedure. By using DRL schedule, the current data add to the small literature on temporal deficits induced by 5FU in animals. Using operant paradigms to evaluate chemobrain in rodents may allow for more consistent and sensitive procedures in part because the use of positive reinforcers can allow for more congruence in the functional similarities between tasks [6] . Further, operant tasks may be more likely to elicit frontal cortex mechanisms [7, 19, 25] found to be relevant in human studies on chemobrain. Operant procedures may preclude the necessity to use paradigms that include stressful events (e.g. spatial memory water-maze test) which may unduly influence dependent variables [6] . Lastly, operant procedures provide flexibility in adding task components to increase or decrease task complexity and difficulty.
Second, the current study provides additional utility by measuring behavioral performance prior to and throughout the multiple drug treatments. Specifically, training behavioral performance prior to the experimental phase (i.e. D1, D7, and D14) more closely matches human testing contexts wherein preexisting skills are tested [4, 6] . In contrast, animals in the chemobrain literature are typically exposed to novel behavioral tasks after prolonged exposure to a chemotherapy regimen, thus further separating the functional characteristics of performance across human and animal paradigms. Lastly, the multiple time points used in the current study allowed for an evaluation of the effects of drug conditions on behavior across time.
Finally, there are limitations of the current study. First, there was no untreated group in the current study (i.e. Saline + Saline); therefore, statements regarding KU32 promoting the recovery of DRL performance cannot be made at this time. Second, the sample sizes of the two groups were relatively small (i.e. 5FU + Saline group (n = 5) and 5FU + KU32 group (n = 6)), but significant effects in overall performance were observed following the second treatment (D7) and even larger differences were observed one week from the second treatment (D14). Further, the current study evaluated behavior in the experimental phase for longer than is typical, and variability within groups was considerably small (see Figs. 1-3) . Lastly, two rats in the KU32 + 5FU group did not experience DRL40 schedules; however, this did not affect the statistical significance of any tests.
Conclusion
The current study found that the novel drug KU32 prevented temporal discrimination deficits induced by 5FU following the second administration and one week following the second administration. We further showed that there were no differences in spatial discrimination performance between the two groups at any point or in general across treatment points. Whether relative differences between the two groups exemplifies recovery effects is unknown at this time. The current behavioral paradigm, however, may allow for improved sensitivity to measure treatment effects derived from novel pharmacological agents such as KU-32.
